Literature DB >> 11250004

Nitric oxide: a novel link between synaptic and nonsynaptic transmission.

J P Kiss1, E S Vizi.   

Abstract

Accumulating evidence indicates that nitric oxide (NO) inhibits the function of monoamine transporters. Because the production of NO by neuronal NO synthase (nNOS) is closely related to the activation of NMDA receptors, the level of NO around nNOS-containing synapses reflects the activity of glutamate-mediated neurotransmission. Glutamate participates mainly in synaptic interactions, but with the help of NO, the strength of excitatory input might be nonsynaptically signaled to the surrounding monoaminergic neurons, which can adapt to the changes without receiving glutamatergic input and without synthesizing glutamate receptors. Thus, the effect of NO on transporters represents a new form of interneuronal communication, a nonsynaptic interaction without receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250004     DOI: 10.1016/s0166-2236(00)01745-8

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  75 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter.

Authors:  Bo-Jin Cao; Maarten E A Reith
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Neuroplastic and neuropathological changes in the central nervous system of the Gray mussel Crenomytilus grayanus (Dunker) under environmental stress.

Authors:  Elena P Kotsyuba; Marina A Vaschenko
Journal:  Invert Neurosci       Date:  2010-05-26

4.  Taurine reduces nitrosative stress and nitric oxide synthase expression in high glucose-exposed human Schwann cells.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

5.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

6.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

7.  Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels.

Authors:  Zsuzsanna Sidló; Patricia H Reggio; Margaret E Rice
Journal:  Neurochem Int       Date:  2007-07-22       Impact factor: 3.921

8.  Lamotrigine differently modulates 7-nitroindazole and L-arginine influence on rat maximal dentate gyrus activation.

Authors:  P Sardo; S D'Agostino; F Carletti; V Rizzo; V La Grutta; G Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

9.  S-nitrosylation of endogenous protein tyrosine phosphatases in endothelial insulin signaling.

Authors:  Ming-Fo Hsu; Kuan-Ting Pan; Fan-Yu Chang; Kay-Hooi Khoo; Henning Urlaub; Ching-Feng Cheng; Geen-Dong Chang; Fawaz G Haj; Tzu-Ching Meng
Journal:  Free Radic Biol Med       Date:  2016-08-10       Impact factor: 7.376

10.  Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways.

Authors:  Shi Di; Marc M Maxson; Alier Franco; Jeffrey G Tasker
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.